The new Kidney Care National Plan from the US Department of Health and Human Services focuses on preventing kidney failure, ...

The VOICE trial examined clinical outcomes and safety after administering vadadustat vs EPO during thrice-weekly hemodialysis ...

An investigator reported the results of a prespecified interim analysis of the phase 3 I CAN trial of ravulizumab for immunoglobulin A nephropathy.

Participants in the treatment group experienced a 93.5% reduction in urine soluble C5b9 levels from baseline to 24 months.

Telitacicept was associated with 6 times the odds of a decrease in proteinuria compared with immunosuppressive treatment at 48 weeks.

Living kidney donation is associated with a modestly increased risk of gestational hypertension, preeclampsia, or eclampsia. Women who become pregnant after donating a kidney face increased risks of ...

Sparsentan lowered blood pressure more than irbesartan at week 8, with mean differences of -7.2 mmHg systolic and -5.6 mmHg diastolic.

A bladder-sparing active surveillance program reported on outcomes in patients with muscle-invasive bladder cancer (MIBC).

Keisha L. Gibson, MD, MPH, is a physician scientist and the division chief of Pediatric Nephrology department at UNC School ...

Korean patients with CKD may be more susceptible to the risks of excess protein restriction. A dietary protein intake of less than 0.6 g/kg/d does not appear renoprotective, but instead may increase ...

The randomized VIDEO-KD trial tested the value of an ESKD video decision aid vs usual care for advanced care planning among older patients with advanced CKD.